Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Inclusion Criteria: * \>18 years old * Histologically or cytologically confirmed diagnosis of NSCLC * Unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC patients who have received one prior platinum-based chemotherapy regimen * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria * ECOG performance status score of 0 or 1 * Willing and able to provide written informed consent Exclusion Criteria: * Laboratory values of: * Absolute neutrophil count \< 1500/ul; * Platelet count \< 75,000/ul; * Hemoglobin \< 10 gm/dl; * AST or ALT \> 3 x the upper limit of normal (ULN); * Alkaline phosphatase \> 5 x ULN; * Bilirubin \> 2 x ULN; * Serum creatinine \> 2.0 mg/dL. * Symptomatic or uncontrolled (untreated or treated and progressing) brain metastasis. * Evidence of meningeal metastasis. * Greater than one prior cytotoxic regimen (not counting adjuvant or neoadjuvant cytotoxic chemotherapy if completed \> 12 months prior to cytotoxic regimen). * Chemotherapy, radiation therapy, experimental therapy, immunotherapy or systemic biologic anticancer therapy within 21 days before beginning study treatment. * Significant weight loss \> 10% of body weight in preceding 6 weeks. * Treatment for another cancer within 3 years of enrollment, unless basal cell carcinoma or cervical cancer in situ. * Myocardial infarction within 6 months of enrollment or congestive heart failure rated New York Heart Association (NYHA) Class III or IV. * Uncontrolled hypertension (systolic blood pressure \> 160 mm Hg and diastolic blood pressure \> 110 mm Hg on maximal medical therapy). * Known history of porphyria (testing not required at screening visit). * Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening visit). * Known history of HIV infection (testing not required at screening visit). * Female who is pregnant or lactating (serum pregnancy test is required for all female patients of childbearing potential). * Sexually active male or female of childbearing potential unwilling to use adequate contraceptive protection. * Physical or mental condition that makes patient unable to complete specified follow-up assessments.